Oberon (Tozorakimab) - Emphysema COPD Research Center

Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations and/or Chronic bronchitis (Oberon)

What is the Study?

The study is designed to compare Tozorakimab with standard therapy to decrease the risk of flare-ups in COPD. It is an injected antibody that blocks IL-33, a protein that promotes inflammation and mucus production, thus leading to flare-ups, symptoms and disease progression in patients with COPD

You might qualify for this if you have:

Current or former smoker
COPD with chronic sputum production
Have frequent flare-ups despite being on standard inhaler treatment. A COPD flare-up is when you have an increase or new onset of cough, sputum, wheezing, shortness of breath or chest tightness which requires treatment with antibiotics, steroids, and/or hospitalizations
1 or more flare-ups requiring steroids or antibiotics
and/or hospitalizations

What Will My Role Be in the Study?

If you participate, you will be randomly assigned to receive either injections of the study medication or placebo every 4 weeks. You will come for 15 visits and will be compensated $85 per clinic visit, and parking is provided. You will do questionnaires, lung function tests, daily home lung testing and maintain a daily electronic diary for symptoms. You may also have 2 CT scans, EKG, bloodwork and possibly 2 echocardiograms. You may have the opportunity to be part of a long term extension to continue with the medication.

Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations and/or Chronic bronchitis (Oberon)

What is the Study?

You might qualify for this if you have:

What Will My Role Be in the Study?

Thank You

For Contacting Us!